Keytruda powers Merck to first-quarter beat

(Reuters) - Drugmaker Merck & Co reported a better-than-expected first-quarter profit on Tuesday and raised its adjusted earnings forecast for the year, helped by a more than 150 percent rise in sales of cancer drug Keytruda.

Keytruda powers Merck to first-quarter beat
Read More


Bagikan Berita Ini